Cetilistat is the second pancreatic lipase inhibitor to be developed following orlistat (Xenical). Inpreclinical studies, cetilistat inhibited pancreatic lipase with high selectivity. In short-term (**-week) phase II trials, cetilistat administration to obese individuals, including some with type 2 diabetes, resulted in significant placebo-subtracted weight losses of up to 1.7 kg and small improvements in LDL cholesterol; glycated hemoglobin (HbA1c) levels were reduced in patients with type 2 diabetes.

The magnitude of weight loss produced by cetilistat is similar to other approved antiobesity agents after *2 weeks,moreover the magnitude of weight loss produced by cetilistat is similar to other approved antiobesity agents after *4 weeks.And there is a major putative advantage of cetilistat who has a lower incidence of gastrointestinal adverse events than orlistat.